Seasonal affective disorder (SAD)

Access:
professional

Article type:
drug information

As we enter the shortest days of the year, some patients may experience depression and for many this is a recurring event. Recurrent major depressive disorder with seasonal pattern, more commonly known as seasonal affective disorder (SAD), affects two to three per cent of all Canadians.¹ A milder form (“winter blues”) affects up to 10 to 20 per cent.² Symptoms generally occur in the fall or winter and remit by spring, though a minority of patients experience the opposite pattern (summer SAD). The incidence increases with latitude, and is more common between 20 and 50 years, and in women.¹⁻³ The etiology of SAD remains unclear, but it is hypothesized that circadian rhythms and genetic factors are involved, and that serotonin, catecholamines, and melatonin also play a role.¹

Light therapy remains one of the main treatments for winter SAD.⁴,⁵ However, questions remain about what is optimal light therapy (e.g. spectrum and intensity/dose).⁶,⁷ A Swedish health technology assessment found that light therapy improved depression scores in the first few weeks of therapy compared to placebo, but the effect diminished over time.⁵ Light therapy had no benefit when looking at clinical response (a 50 per cent reduction in depression score) as the outcome. Side effects, however, tend to be mild and include agitation, headache, eye strain and nausea. Hypomania has been reported with the initiation of light therapy. Blue wavelength light may harm the retina.

Various drug therapies have been studied for SAD (Table 1), with the majority of studies focusing on SSRIs and newer antidepressants. Although there are many reports of positive effects with medications, the quality of evidence overall is also poor. Of note, tricyclic antidepressants are not recommended since their sedating effects can exacerbate sleepiness and lethargy that accompanies SAD⁸, and there is a lack of evidence of benefit.
Extended-release bupropion is the only pharmacological therapy officially indicated for the prevention of SAD,\textsuperscript{9,10} although other serotonergic antidepressants may also be effective.\textsuperscript{11} Preventative treatment is usually started in the fall before the anticipated onset of symptoms, and tapered off in the spring, four to six months later.

Light therapy or drug therapy?

There are few direct comparisons between light therapy and medication so it is not possible to make a specific recommendation. Initial treatment decisions may be made on factors such as preference, convenience, and costs. Light therapy is considered generally "low risk",\textsuperscript{4} but does require a daily time commitment.\textsuperscript{12} A recent Canadian study comparing the total health care costs of light therapy versus fluoxetine (two therapies that have been reported to be equally effective) found that while purchasing a light box might cost more up front, after the first year of treatment light therapy starts to cost less, especially if fluoxetine doses are greater than 20 mg/d.\textsuperscript{13}

Summary:

Patients suffering from seasonal affective disorder may benefit from light or drug, but the overall quality of evidence, especially for drug therapy is low. Bupropion is the most effective drug treatment.
<table>
<thead>
<tr>
<th>Table 1: Drug therapies for SAD</th>
</tr>
</thead>
</table>
| **SSRIs**                     | Fluoxetine 20 mg/d vs placebo: clinical response* 59% vs 34% (p<0.05, n=68)\(^{13}\)  
Fluoxetine 20 mg/d vs light therapy: fluoxetine response 65%; remission 70%; bright light response 70%; remission 50% (n=35)\(^{15}\)  
Fluoxetine 20 mg compared to light therapy: 67% response in each, fluoxetine 54% remission; light 50% (n=96)\(^{16}\)  
Sertraline 50-200 mg/d x 8 weeks: significant reduction in anxiety and depression scores for sertraline compared to placebo, but no significant difference in proportion of responders (56% vs 50%) (n=187)\(^{17}\)  
Escitalopram 10-20 mg/d: response rate 95%, remission 85% (n=20), 8 weeks\(^{18}\) |
| **Duloxetine (SNRI)**         | Duloxetine 60-120 mg daily for 8 weeks improved depression scores, social functioning, and reduced lost productivity in one open label study. The median time to improvement was 4 weeks.\(^{19}\) |
| **Bupropion (NDRI)**          | Bupropion 200-400 mg/d produced complete or partial response in 72-83% of severely depressed patients with SAD in one small open-label study. Bupropion XL 150-300 mg/d reduced recurrence of depression in previous antidepressant studies by 44% compared to placebo (total n=1042)\(^{9}\) |
| **Moclobemide**               | Moclobemide 400 mg/d was no better than placebo in improving overall depression scores after 3 weeks, but seemed to improve symptoms of hypomania, hyperphagia, and carbohydrate craving.\(^{21}\)  
Moclobemide 300-450 mg/d x 6 weeks was beneficial in about two-thirds of patients with SAD in one small open-label study (n=11)\(^{22}\) |
| **Melatonin**                 | Low-dose melatonin (0.125 mg) given 8 and 12 hours after waking in patients with subsyndromal SAD, controlled-release melatonin (2 hours before bed) improved sleep and vitality ratings compared to placebo (n=13)\(^{24}\) |
| **St John's wort**            | 900 mg daily of Hypericum extract LI 160 reduced depression scores by 70% in a small group of patients with SAD (n=20). There was a trend for increased response in patients who received bright light treatment in addition.\(^{25}\) |
| **Ginkgo biloba extract**     | Ginkgo biloba extract PN245 was no better than placebo in preventing depression (n=27)\(^{26}\) |
| **Vitamin D**                 | Despite anecdotal claims that the sunshine vitamin helps winter depression, some evidence that it elevates mood, there is no strong evidence for SAD.\(^{27,28}\) Vitamin D supplementation did not result in differences in health scores among older women compared to placebo (n=2117)\(^{29}\) |
| **Other**                     | There is some evidence that modafinil, tryptophan, the serotonin-norepinephrine reuptake inhibitor reboxetine**, and the serotonin agonist agomelatine also be beneficial. Alprazolam, vitamin B12, and levodopa/carbidopa effective.\(^{30-35}\) |

\(^{13}\) Haddad et al. 2001  
\(^{15}\) Jakobsen et al. 2001  
\(^{16}\) Haddad et al. 2002  
\(^{17}\) Aamdal et al. 2003  
\(^{18}\) Haddad et al. 2004  
\(^{19}\) Haddad et al. 2005  
\(^{20}\) Haddad et al. 2006  
\(^{21}\) Haddad et al. 2007  
\(^{22}\) Haddad et al. 2008  
\(^{23}\) Haddad et al. 2009  
\(^{24}\) Haddad et al. 2010  
\(^{25}\) Haddad et al. 2011  
\(^{26}\) Haddad et al. 2012  
\(^{27}\) Haddad et al. 2013  
\(^{28}\) Haddad et al. 2014  
\(^{29}\) Haddad et al. 2015  
\(^{30}\) Haddad et al. 2016  
\(^{31}\) Haddad et al. 2017  
\(^{32}\) Haddad et al. 2018  
\(^{33}\) Haddad et al. 2019  
\(^{34}\) Haddad et al. 2020  
\(^{35}\) Haddad et al. 2021  
\(^{**}\) Reboxetine is not currently approved for depression in the United States.  

\*Clinical response defined as a 50% reduction in depression rating scores  
\footnote{RCT: randomized controlled trial}
References:


3. Diagnostic and statistical manual DSM-IV-TR (online via Stat!Ref)


10. e-CPS


